Real-world data on the incidence and risk of Guillain-Barre syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.

ABSTRACT: Increasing evidence suggests an association between SARS-CoV-2 vaccines and Guillain-Barré syndrome (GBS). Nevertheless, little is understood about the contributing risk factors and clinical characteristics of GBS post SARS-CoV-2 vaccination. In this prospective surveillance study of 38,828,691 SARS-CoV-2 vaccine doses administered from February 2021 to March 2022 in the Gyeonggi Province, South Korea, 55 cases of GBS were reported post vaccination. We estimated the incidence rate of GBS per million doses and the incidence rate ratio for the vaccine dose, mechanism, age, and sex. Additionally, we compared the clinical characteristics of GBS following mRNA-based and viral vector-based vaccinations. The overall incidence of GBS following SARS-CoV-2 vaccination was 1.42 per million doses. Vir

SUBMITTER: Ha J 

PROVIDER: S-EPMC9989583 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature